Overview

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

Status:
Completed

Trial end date:
2018-04-09

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

MedImmune LLC

Treatments:

Benralizumab